MCTC - Achieves Sub-Micron Polymeric Particles of Cannabidiol (CBD) and TPGS - Files Cannabinoid Nanoparticle Patent

LOS ANGELES, CA / ACCESSWIRE /September 25, 2019 / MCTC Holdings, Inc. (OTCPINK:MCTC) an emerging company in the cannabinoid technology marketplace, today announces a major development milestone in its research and development program aimed at creating new cannabinoid and cannabis extract delivery technologies for foods, beverages and consumer products. By combining cannabidiol with d-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS), a water soluble form of vitamin E, the Company has created nanoparticles that are expected to yield unmatched bioavailability and formulation flexibility. The Company has filed a patent application relative to the invention.

Chief Executive Officer, Arman Tabatabsei, commented. "It is well documented in the peer reviewed literature that polymeric nanoparticles adapted for oral delivery of poorly soluble compounds can significantly improve absorption and bioavailability. Additionally, it is well documented that TPGS is a powerful, yet safe, emulsifier and bioavailability enhancer of hydrophobic compounds. By combining these two proven bioenhancement techniques into a unique nanoparticle design, MCTC researchers have developed something extraordinary."

The patent filing being announced today is the Company's second filing this month. Last week, MCTC filed a patent application for its unique edible cannabinoid delivery and packaging technology enhanced with solid polymeric nanoparticles.

Mr. Tabatabaei continued, "The polymer based nanoparticles we are developing should not be confused with the simple oil-in-water nanoemulsions being marketed as interim solutions to the food and beverage industry, as these two technologies are significantly different. The polymer based particles we are developing will allow for significant loading of active ingredients and unparalleled flexibility in creating custom cannabinoid combinations with unique performance characteristics. We believe this will be an important technology area for the cannabinoid formulation marketplace."

TPGS was developed in the 1950's in order to supplement the dietary needs of vitamin E deficient children and exotic animals. Pharmaceutical formulators soon thereafter realized the strong bioenhancement and emulsification properties of the compound and since, dozens of peer reviewed studies have been published documenting the safety and the unique properties of TPGS. Over the past ten years, formulators have increased the use of TPGS as an ever larger number of active ingredients are water insoluble. The Company is applying these technologies to cannabinoids, which are also highly water insoluble.

MCTC plans to continue to build its IP portfolio while productizing selected forms of its developed technologies, especially relating to cannabinoid functional food, beverage and transdermal ingredients.

About MCTC Holdings, Inc.

MCTC Holdings, Inc. (d/b/a: Cannabis Global) is a Delaware registered, fully reporting and audited publicly-traded company. With the hemp and cannabis industries moving very quickly and with a growing number of market entrants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The Company plans to actively pursue R&D programs and productization for exotic cannabinoid isolation, bioenhancement of cannabinoids and polymeric solid nanoparticles and nanofibers for addition into consumer products and for dermal application. The Company is headed and managed by a group of highly experienced cannabis industry pioneers and entrepreneurs.

More information on the Company can be viewed at www.CannabisGlobalinc.com.

For more information, please contact:
Arman Tabatabaei
IR@cannabisglobalinc.com

Forward-looking Statements

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-k, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

SOURCE: MCTC Holdings, Inc



View source version on accesswire.com:
https://www.accesswire.com/560871/MCTC--Achieves-Sub-Micron-Polymeric-Particles-of-Cannabidiol-CBD-and-TPGS--Files-Cannabinoid-Nanoparticle-Patent

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.